Retinal Specialist versus Artificial Intelligence Detection of Retinal Fluid from OCT

Written by: Mohsin H. Ali, MD December 2020 Keenan TDL, Clemons TE, Domalpally A, Elman MJ, Havilio M, Agrón E, Benyamini G, Chew EY. Retinal Specialist versus Artificial Intelligence Detection of Retinal Fluid from OCT: Age-Related Eye Disease Study 2: 10-Year Follow-On Study. Ophthalmology. 2020 Jun 27:S0161-6420(20)30580-7. doi: 10.1016/j.ophtha.2020.06.038. Epub ahead of print. PMID: 32598950. […]

Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry

Written by: Rehan M. Hussain, MD December 2020 Gabrielle PH, Nguyen V, Wolff B, et al. Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry. Ophthalmol Retina 2020 Sep;4(9):861-870. doi: 10.1016/j.oret.2020.06.020. Epub 2020 Jun 20. It is well […]

Randomized Safety and Feasibility Trial of Ultra-Rapid Cooling Anesthesia for Intravitreal Injections

Written by: Akshay S. Thomas, MD November 2020 Besirli CG, Smith SJ, Zacks DN, Gardner TW, Pipe KP, Musch DC, Shah AR. Randomized Safety and Feasibility Trial of Ultra-Rapid Cooling Anesthesia for Intravitreal Injections. Ophthalmol Retina. 2020 Oct;4(10):979-986. doi: 10.1016/j.oret.2020.04.001. Epub 2020 Apr 15. PMID: 32446842; PMCID: PMC7541410. Intravitreal injection is by far the most […]

Paracentral and Cecocentral Scotomas after Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment

Written by: Vlad Matei, MD November 2020 Khurana RN, Patel VR. Paracentral and cecocentral scotomas after pars plana vitrectomy for rhegmatogenous retinal detachment. Am J Ophthalmol 2020;219:163-169. Pars plana vitrectomy (PPV) is the most commonly employed procedure in the repair of rhegmatogenous retinal detachment (RRD). While preoperative factors, especially the degree of macular detachment, most […]

Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice

Written by: Joshua D. Levinson, MD November 2020 Maloney MH, Payne SR, Herrin J, et al. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmol. Published online August 2020. doi:10.1016/j.ophtha.2020.07.062 Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have become the standard of care in the treatment of multiple […]

Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial

November 2020 Lim TH, Lai TYY, Takahashi K et al. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial. JAMA Ophthalmol. Sept 2020; 138(9): 935-942. Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration characterized by aneurysmal polypoidal lesions best imaged with […]

C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial

Written by: Katherine E. Talcott, MD October 2020 Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA, C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial, Ophthalmology (2020), doi: https://doi.org/10.1016/j.ophtha.2020.08.027. While there are multiple treatment […]